Urothelial Cancer

Roberto Iacovelli, MD, PhD, discusses the patient eligibility criteria of the phase 2 ARIES trial in urothelial cancer.

The addition of the selective oncolytic adenovirus CG0070 to pembrolizumab showed encouraging activity and safety in Bacillus Calmette-Guerin–unresponsive non-muscle invasive bladder cancer, according to early data from the phase 2 CORE1 trial.

Avelumab is now a treatment option for patients with urothelial cancer in the United Kingdom following a recommendation from the National Institute for Health and Care Excellence issued Thursday, April 7, 2022.1

The European Commission has approved nivolumab for use in the adjuvant treatment of adult patients with muscle-invasive urothelial carcinoma and a PD-L1 expression of 1% or higher on tumor cells, who are at a high risk of recurrence following radical resection.

Nab-paclitaxel plus pembrolizumab produced an encouraging overall response rate with manageable safety in patients with advanced urothelial cancer who were refractory to platinum-based chemotherapy or cisplatin ineligible, according to data from the phase 2 ABLE trial.

Roberto Iacovelli, MD, PhD, discusses the potential next steps of the phase 2 ARIES trial in urothelial cancer.

Effective treatment paths leveraging neoadjuvant chemotherapy have been well-established for patients with muscle-invasive bladder cancer, with mounting retrospective and prospective data continuing to demonstrate overall survival benefit compared with adjuvant chemotherapy.

Daniel P. Petrylak, MD, discusses the rationale for of the phase 1b/2 EV-103 trial in patients with muscle-invasive bladder cancer.

Patients with metastatic urothelial carcinoma have multiple effective treatment options approved in both the first line and relapsed settings, with other promising agents and combinations currently in development.

Brian Ramnaraign, MD, discusses sequencing immunotherapy and tyrosine kinase inhibitor combinations in metastatic renal cell carcinoma.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has confirmed its recommendation to approve the use of enfortumab vedotin in adult patients with locally advanced or metastatic urothelial cancer who have received prior platinum-based chemotherapy and a PD-1/PD-L1 inhibitor.

Roberto Iacovelli, MD, PhD, discusses the rationale of the phase 2 ARIES trial in urothelial cancer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nivolumab for use as an adjuvant treatment in adult patients with muscle-invasive urothelial carcinoma with a PD-L1 expression of at least 1% on tumor cells, who are at a high risk of recurrence following radical resection.

The addition of atezolizumab to neoadjuvant gemcitabine and cisplatin generated a high rate of non–muscle-invasive downstaging following radical cystectomy, which correlated with improved relapse-free survival and overall survival in patients with muscle-invasive bladder cancer, according to data from a phase 2 trial.

Enfortumab vedotin produced promising antitumor activity when used as neoadjuvant treatment in patients with muscle invasive bladder cancer who were not eligible for cisplatin.

OncLive® speaks with Drs. Jonathan Rosenberg and Guru Sonpavde on the groundbreaking research being presented in bladder cancer.

The addition of olaparib to durvalumab did not result in a significant prolongation in progression-free survival compared with durvalumab alone in patients with previously untreated, platinum-ineligible metastatic urothelial carcinoma.

Second-line sacituzumab govitecan plus pembrolizumab generated promising antitumor activity in patients with checkpoint inhibitor–naïve metastatic urothelial cancer.

Niraparib in combination with cabozantinib demonstrated a manageable safety profile, with preliminary efficacy observed in heavily pretreated patients with metastatic urothelial carcinoma.

Daniel P. Petrylak, MD, discusses the utilization of enfortumab vedotin-ejfv in patients with muscle-invasive bladder cancer (MIBC).

Roberto Iacovelli, MD, PhD, discusses efficacy findings from the phase 2 ARIES trial in urothelial cancer.

Avelumab failed to demonstrate an improvement in overall survival at 1 year as frontline treatment in patients with cisplatin-ineligible, PD-L1–positive advanced urothelial cancer, though it did elicit a notable objective response rate.

The frontline maintenance combination of avelumab plus best supportive care continued to show an improvement in overall survival compared with BSC alone in patients with metastatic urothelial cancer who receive first-line chemotherapy.

The combination of lenvatinib and pembrolizumab elicited comparable antitumor activity compared with placebo plus pembrolizumab as frontline therapy in patients with advanced urothelial carcinoma who were ineligible for platinum-based chemotherapy, according to data from LEAP-011.

Jonathan A. Chatzkel, MD, discusses the future treatment options in bladder cancer.

Phillip Palmbos, MD, PhD, discusses the utilization of adjuvant nivolumab following cystectomy in high-risk, muscle-invasive bladder cancer.

Expert reflection on the current unmet needs in metastatic urothelial carcinoma and hope for future improvements in the treatment armamentarium.

Following frontline maintenance therapy in metastatic urothelial carcinoma, Ignacio Duran, MD, PhD, considers optimal second-line treatment options.

The novel non-viral gene therapy, EG-70, produced a complete response rate of 83% at 3 months in evaluable patients with high-grade non–muscle invasive bladder cancer with carcinoma in situ who were unresponsive to Bacillus Calmette-Guérin.

Ali R. Khaki, MD, comments on how to treat patients with advanced bladder cancer based on data demonstrated by the EV-103 study of enfortumab vedotin.